Elite controllers as a model of functional cure, Current Opinion in HIV and AIDS, vol.6, issue.3 ,
DOI : 10.1097/COH.0b013e328345a328
Elite control of HIV Infection: implications for vaccines and treatment 15:134?136. 96 3. Saez?Cirion A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? 97, Top HIV Med Immunological reviews, vol.95, issue.254, pp.281-294, 2007. ,
Immune and Viral Correlates of ???Secondary Viral Control??? after Treatment Interruption in Chronically HIV-1 Infected Patients, PLoS ONE, vol.83, issue.5, pp.37792-101, 2012. ,
DOI : 10.1371/journal.pone.0037792.s001
CD4+ count?guided 105 interruption of antiretroviral treatment, N Engl J Med, vol.355, pp.2283-2296, 2006. ,
CD4?guided structured antiretroviral 107 treatment interruption strategy in HIV?infected adults in west Africa (Trivacan ANRS 1269 trial): a 108 randomised trial, Lancet, vol.367, issue.8, 2006. ,
Immune control of HIV?1 110 after early treatment of acute infection, Nature, vol.407, issue.9, pp.523-526, 2000. ,
Limited Durability of Viral Control following Treated Acute HIV Infection, PLoS Medicine, vol.200, issue.2, pp.36-46, 2004. ,
DOI : 10.1371/journal.pmed.0010036.sd004
Antiretroviral therapy in acute and 114 recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. 115, AIDS, vol.23, issue.116, p.11, 2009. ,
Early antiretroviral therapy during 117 primary HIV?1 infection results in a transient reduction of the viral setpoint upon treatment 118 interruption, PLoS One, vol.6, issue.119, pp.27463-27475, 2011. ,
Short?course antiretroviral therapy in 123 primary HIV infection, N Engl J Med, vol.368, issue.124, pp.207-217, 2013. ,
Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection, PLoS ONE, vol.7, issue.8, pp.43754-127, 2012. ,
DOI : 10.1371/journal.pone.0043754.t003
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy, AIDS, vol.22, issue.13, pp.1583-1588, 2008. ,
DOI : 10.1097/QAD.0b013e328305bd77
Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection, AIDS, vol.24, issue.10, pp.1598-1601, 2010. ,
DOI : 10.1097/QAD.0b013e32833b61ba
HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy, Antiviral Therapy, vol.17, issue.6, pp.1001-1009, 2012. ,
DOI : 10.3851/IMP2273
Immunovirologic control 24 months 137 after interruption of antiretroviral therapy initiated close to HIV seroconversion, Arch Intern Med, vol.138, issue.139, pp.1721252-1255, 2012. ,
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells, Nature Medicine, vol.9, issue.6, pp.727-728, 2003. ,
DOI : 10.1038/nm880
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?, AIDS, vol.25, issue.7, pp.885-897, 2011. ,
DOI : 10.1097/QAD.0b013e3283467041
Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy, Journal of Medical Virology, vol.3, issue.6, pp.885-889, 2012. ,
DOI : 10.1002/jmv.23297
Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study, BMC Research Notes, vol.5, issue.1, p.578, 2012. ,
DOI : 10.1086/432881